NCT04983901 2024-11-04PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONINM.D. Anderson Cancer CenterPhase 2 Completed100 enrolled 38 charts
NCT03485950 2022-03-15Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-TazobactamM.D. Anderson Cancer CenterPhase 2 Completed100 enrolled 33 charts